Details of the Drug

General Information of Drug (ID: DM4K7GQ)

Drug Name
Erythromycin
Synonyms
Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [1]
Acute gonococcal cervicitis N.A. Approved [1]
Acute otitis media AB00 Approved [1]
Bacteremia 1A73 Approved [1]
Bacterial infection 1A00-1C4Z Approved [2]
Cholangitis N.A. Approved [1]
Gastroparesis DA41.00 Approved [1]
Hepatic coma N.A. Approved [1]
Inclusion conjunctivitis N.A. Approved [1]
Legionnaires' disease N.A. Approved [1]
Listeriosis N.A. Approved [1]
Mycoplasma pneumoniae pneumonia N.A. Approved [1]
Preterm premature rupture of the membranes N.A. Approved [1]
Staphylococcus aureus infection N.A. Approved [1]
Streptococcal pneumonia N.A. Approved [1]
Syphilis N.A. Approved [1]
Urinary tract infection GC08 Approved [1]
Erythema ME64.0 Investigative [1]
Pneumonia caused by chlamydia N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 733.9
Logarithm of the Partition Coefficient (xlogp) 2.7
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 7.3 +/- 3.9 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1.8 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.2 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Clearance
The clearance of drug is 0.53 +/- 0.13 L/h/kg [5]
Elimination
Under 5% of the orally administered dose of erythromycin is found excreted in the urine [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.5 hours [7]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 90.87869 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.1% [9]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.95 L/kg [9]
Water Solubility
The ability of drug to dissolve in water is measured as 2.1 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Gastrointestinal disorders Not Available GPT OTOXOA0Q [10]
Torsade de pointes Not Available KCNQ1 OT8SPJNX [10]
Torsade de pointes Not Available MINK1 OTKB0RA8 [10]
Chemical Identifiers
Formula
C37H67NO13
IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
Canonical SMILES
CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
InChI
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
InChIKey
ULGZDMOVFRHVEP-RWJQBGPGSA-N
Cross-matching ID
PubChem CID
12560
ChEBI ID
CHEBI:42355
CAS Number
114-07-8
DrugBank ID
DB00199
TTD ID
D02YIZ
VARIDT ID
DR00050
INTEDE ID
DR0614
ACDINA ID
D00241
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA) TTUWYEA NOUNIPROTAC Binder [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [12]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [13]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [15]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [16]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [17]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [18]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [19]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [20]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Substrate [18]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [21]
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DEIZLTN CP4FB_HUMAN Substrate [22]
Beta-glucuronidase (uidA) DE7IQ34 A0A2A5L2J1_LACRH Substrate [23], [24]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Gene/Protein Processing [25]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Drug Response [10]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Gene/Protein Processing [25]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [26]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [27]
Cytochrome P450 11B2, mitochondrial (CYP11B2) OTIOLWYN C11B2_HUMAN Gene/Protein Processing [28]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [29]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Biotransformations [30]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Gene/Protein Processing [31]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Gene/Protein Processing [25]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Erythromycin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Ofloxacin. Bacterial infection [1A00-1C4Z] [32]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [33]
Dalfopristin DM4LTKV Major Decreased metabolism of Erythromycin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [34]
Clarithromycin DM4M1SG Major Decreased metabolism of Erythromycin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Erythromycin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [32]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [32]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Norfloxacin. Bacterial infection [1A00-1C4Z] [32]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Levofloxacin. Bacterial infection [1A00-1C4Z] [32]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Erythromycin and Moxifloxacin. Bacterial infection [1A00-1C4Z] [36]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [33]
Telithromycin DMZ4P3A Major Decreased metabolism of Erythromycin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
⏷ Show the Full List of 11 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Erythromycin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [37]
Methylergonovine DMBEX4O Major Decreased metabolism of Erythromycin caused by Methylergonovine mediated inhibition of CYP450 enzyme. Abortion [JA00] [38]
Clindamycin DM15HL8 Moderate Competitive binding of the 50S ribosomal subunit when Erythromycin and Clindamycin are combined. Acne vulgaris [ED80] [39]
Tretinoin DM49DUI Moderate Decreased metabolism of Erythromycin caused by Tretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [40]
Repaglinide DM5SXUV Moderate Decreased metabolism of Erythromycin caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [41]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Erythromycin caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [42]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Thioguanine. Acute myeloid leukaemia [2A60] [43]
Ivosidenib DM8S6T7 Major Increased metabolism of Erythromycin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [44]
Midostaurin DMI6E0R Moderate Decreased metabolism of Erythromycin caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [45]
Idarubicin DMM0XGL Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [46]
Daunorubicin DMQUSBT Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [46]
Arn-509 DMT81LZ Moderate Accelerated clearance of Erythromycin due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [47]
Gilteritinib DMTI0ZO Moderate Decreased metabolism of Erythromycin caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [47]
Oliceridine DM6MDCF Major Decreased metabolism of Erythromycin caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [48]
Loratadine DMF3AN7 Minor Decreased metabolism of Erythromycin caused by Loratadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [49]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Tacrine. Alzheimer disease [8A20] [33]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Galantamine. Alzheimer disease [8A20] [33]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Rivastigmine. Alzheimer disease [8A20] [33]
Donepezil DMIYG7Z Minor Decreased metabolism of Erythromycin caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [50]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Erythromycin and Metronidazole. Amoebiasis [1A36] [37]
Ranolazine DM0C9IL Major Decreased metabolism of Erythromycin caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [51]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Erythromycin and Bepridil. Angina pectoris [BA40] [33]
Dronedarone DMA8FS5 Major Decreased metabolism of Erythromycin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [37]
Nifedipine DMSVOZT Moderate Decreased metabolism of Erythromycin caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [52]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Erythromycin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [53]
Buspirone DMBS632 Moderate Decreased metabolism of Erythromycin caused by Buspirone mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [37]
Clorazepate DMC3JST Moderate Decreased metabolism of Erythromycin caused by Clorazepate mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [54]
Alprazolam DMC7XDN Moderate Decreased metabolism of Erythromycin caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [55]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [33]
Halazepam DMPFWO6 Moderate Decreased metabolism of Erythromycin caused by Halazepam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [55]
Chlordiazepoxide DMTN5XI Moderate Decreased metabolism of Erythromycin caused by Chlordiazepoxide mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [55]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Erythromycin caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [55]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Promazine. Appearance/behaviour symptom [MB23] [33]
Cilostazol DMZMSCT Major Decreased metabolism of Erythromycin caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [47]
Voriconazole DMAOL2S Major Decreased metabolism of Erythromycin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [35]
Posaconazole DMUL5EW Major Decreased metabolism of Erythromycin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [35]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Levalbuterol. Asthma [CA23] [56]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Terbutaline. Asthma [CA23] [57]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Pirbuterol. Asthma [CA23] [57]
Isoetharine DMITSEH Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Isoetharine. Asthma [CA23] [57]
Budesonide DMJIBAW Moderate Decreased metabolism of Erythromycin caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [58]
Aminophylline DML2NIB Moderate Decreased metabolism of Erythromycin caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [59]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Salbutamol. Asthma [CA23] [56]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Erythromycin caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [60]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Formoterol. Asthma [CA23] [57]
Pimecrolimus DMZLGRB Minor Decreased metabolism of Erythromycin caused by Pimecrolimus mediated inhibition of CYP450 enzyme. Atopic eczema [EA80] [61]
Atomoxetine DM5L6HI Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [33]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [47]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Desipramine. Attention deficit hyperactivity disorder [6A05] [33]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Retigabine. Behcet disease [4A62] [33]
Cariprazine DMJYDVK Moderate Decreased metabolism of Erythromycin caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [62]
Erdafitinib DMI782S Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [63]
Loperamide DMOJZQ9 Major Decreased clearance of Erythromycin due to the transporter inhibition by Loperamide. Bowel habit change [ME05] [64]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Eribulin. Breast cancer [2C60-2C6Y] [33]
Talazoparib DM1KS78 Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [47]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Erythromycin caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [65]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Erythromycin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [66]
HKI-272 DM6QOVN Major Decreased metabolism of Erythromycin caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [67]
LY2835219 DM93VBZ Moderate Decreased metabolism of Erythromycin caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [68]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Erythromycin caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Tucatinib DMBESUA Major Decreased metabolism of Erythromycin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Palbociclib DMD7L94 Moderate Decreased metabolism of Erythromycin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Erythromycin caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Tamoxifen. Breast cancer [2C60-2C6Y] [33]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Erythromycin caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [69]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Erythromycin and Toremifene. Breast cancer [2C60-2C6Y] [33]
Bosutinib DMTI8YE Major Decreased metabolism of Erythromycin caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Estradiol DMUNTE3 Moderate Decreased metabolism of Erythromycin caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Erythromycin and Grepafloxacin. Bronchitis [CA20] [32]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Erythromycin and Sotalol. Cardiac arrhythmia [BC9Z] [33]
Dofetilide DMPN1TW Major Increased risk of prolong QT interval by the combination of Erythromycin and Dofetilide. Cardiac arrhythmia [BC9Z] [33]
Atorvastatin DMF28YC Major Decreased metabolism of Erythromycin caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [70]
Macitentan DMP79A1 Major Decreased metabolism of Erythromycin caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [71]
PF-04449913 DMSB068 Moderate Decreased metabolism of Erythromycin caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [72]
Fluorometholone DM2HKC4 Moderate Decreased metabolism of Erythromycin caused by Fluorometholone mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [73]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [57]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [56]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [57]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [57]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [57]
Fidaxomicin DMFP6MV Minor Decreased clearance of Erythromycin due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [74]
Anisindione DM2C48U Major Decreased metabolism of Erythromycin caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [75]
Regorafenib DMHSY1I Moderate Decreased metabolism of Erythromycin caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [37]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Erythromycin caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [33]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Oxaliplatin. Colorectal cancer [2B91] [33]
Intedanib DMSTA36 Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [76]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Isoproterenol. Conduction disorder [BC63] [56]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Erythromycin caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [37]
Ulipristal DMBNI20 Minor Decreased metabolism of Erythromycin caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [47]
Etonogestrel DMKA8J4 Moderate Decreased metabolism of Erythromycin caused by Etonogestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [37]
Levobupivacaine DM783CH Moderate Decreased metabolism of Erythromycin caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [47]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Halothane. Corneal disease [9A76-9A78] [33]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Propofol. Corneal disease [9A76-9A78] [77]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Sevoflurane. Corneal disease [9A76-9A78] [33]
Ropivacaine DMSPJG2 Minor Decreased metabolism of Erythromycin caused by Ropivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [78]
Alfentanil DMVO0UB Major Decreased metabolism of Erythromycin caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [79]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Erythromycin caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [59]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Erythromycin and Methadone. Cough [MD12] [33]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Clofazimine. Crohn disease [DD70] [80]
Mycophenolic acid DMRBMAU Moderate Altered absorption of Erythromycin due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [81]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Erythromycin and Mifepristone. Cushing syndrome [5A70] [33]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Erythromycin and Pasireotide. Cushing syndrome [5A70] [33]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Osilodrostat. Cushing syndrome [5A70] [47]
Ivacaftor DMZC1HS Major Decreased metabolism of Erythromycin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [47]
Ethanol DMDRQZU Minor Altered absorption of Erythromycin due to GI dynamics variation caused by Ethanol. Cystitis [GC00] [82]
MK-8228 DMOB58Q Moderate Decreased metabolism of Erythromycin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [83]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Erythromycin caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [84]
Aprepitant DM053KT Moderate Decreased metabolism of Erythromycin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [85]
Sertraline DM0FB1J Moderate Decreased metabolism of Erythromycin caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [86]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Trimipramine. Depression [6A70-6A7Z] [33]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Imipramine. Depression [6A70-6A7Z] [33]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Erythromycin caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [86]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Nortriptyline. Depression [6A70-6A7Z] [33]
Vilazodone DM4LECQ Moderate Decreased metabolism of Erythromycin caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [87]
Nefazodone DM4ZS8M Major Decreased metabolism of Erythromycin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Paroxetine DM5PVQE Moderate Decreased metabolism of Erythromycin caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [86]
OPC-34712 DMHG57U Major Decreased metabolism of Erythromycin caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [88]
Trazodone DMK1GBJ Moderate Decreased metabolism of Erythromycin caused by Trazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [89]
Amitriptyline DMK7F9S Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Amitriptyline. Depression [6A70-6A7Z] [33]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Amoxapine. Depression [6A70-6A7Z] [33]
Mirtazapine DML53ZJ Moderate Decreased metabolism of Erythromycin caused by Mirtazapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [90]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Maprotiline. Depression [6A70-6A7Z] [33]
Venlafaxine DMR6QH0 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Venlafaxine. Depression [6A70-6A7Z] [37]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Erythromycin caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [91]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Erythromycin caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [37]
Citalopram derivative 1 DMITX1G Major Increased risk of prolong QT interval by the combination of Erythromycin and Citalopram derivative 1. Discovery agent [N.A.] [33]
PMID28870136-Compound-48 DMPIM9L Moderate Decreased metabolism of Erythromycin caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [59]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [33]
Ospemifene DMC4GEI Moderate Decreased metabolism of Erythromycin caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [92]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Deutetrabenazine. Dystonic disorder [8A02] [93]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Ingrezza. Dystonic disorder [8A02] [94]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Erythromycin caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [95]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Erythromycin caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [96]
Mephenytoin DM5UGDK Moderate Increased metabolism of Erythromycin caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [97]
Cenobamate DM8KLU9 Moderate Increased metabolism of Erythromycin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Stiripentol DMMSDOY Moderate Decreased metabolism of Erythromycin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Phenytoin DMNOKBV Moderate Increased metabolism of Erythromycin caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [97]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Erythromycin caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [97]
Clonazepam DMTO13J Moderate Decreased metabolism of Erythromycin caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Ethotoin DMXWOCP Moderate Increased metabolism of Erythromycin caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [97]
Cannabidiol DM0659E Minor Decreased metabolism of Erythromycin caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [47]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Erythromycin caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [99]
Tazemetostat DMWP1BH Major Decreased metabolism of Erythromycin caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [100]
Solifenacin DMG592Q Major Decreased metabolism of Erythromycin caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [37]
Mirabegron DMS1GYT Minor Decreased metabolism of Erythromycin caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [101]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Erythromycin caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [102]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Erythromycin caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [103]
Itraconazole DMCR1MV Major Decreased metabolism of Erythromycin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [35]
Ketoconazole DMPZI3Q Major Decreased metabolism of Erythromycin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [35]
Cimetidine DMH61ZB Moderate Decreased metabolism of Erythromycin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [37]
Cisapride DMY7PED Major Decreased metabolism of Erythromycin caused by Cisapride mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [55]
Ripretinib DM958QB Moderate Decreased metabolism of Erythromycin caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [37]
Sunitinib DMCBJSR Moderate Decreased metabolism of Erythromycin caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [37]
Avapritinib DMK2GZX Major Decreased metabolism of Erythromycin caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [47]
Colchicine DM2POTE Major Decreased metabolism of Erythromycin caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [104]
Lincomycin DMVTHER Moderate Competitive binding of the 50S ribosomal subunit when Erythromycin and Lincomycin are combined. Gram-positive bacterial infection [1B74-1F40] [39]
Ergotamine DMKR3C5 Major Decreased metabolism of Erythromycin caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [105]
Eplerenone DMF0NQR Major Decreased metabolism of Erythromycin caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [106]
Digoxin DMQCTIH Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Digoxin. Heart failure [BD10-BD1Z] [107]
Digitoxin DMWVIGP Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Digitoxin. Heart failure [BD10-BD1Z] [107]
Boceprevir DMBSHMF Major Decreased metabolism of Erythromycin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Simeprevir DMLUA9D Major Decreased metabolism of Erythromycin caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [37]
Telaprevir DMMRV29 Major Decreased metabolism of Erythromycin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Erythromycin caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [37]
GS-5885 DMSL3DX Moderate Decreased clearance of Erythromycin due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [108]
Rifapentine DMCHV4I Moderate Increased metabolism of Erythromycin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [109]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [110]
Indinavir DM0T3YH Major Decreased metabolism of Erythromycin caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
MK-1439 DM215WE Minor Decreased metabolism of Erythromycin caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [111]
Delavirdine DM3NF5G Major Decreased metabolism of Erythromycin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Erythromycin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Nevirapine DM6HX9B Moderate Increased metabolism of Erythromycin caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Cobicistat DM6L4H2 Major Decreased metabolism of Erythromycin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Erythromycin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [112]
Dolutegravir DMCZGRE Minor Decreased metabolism of Erythromycin caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [113]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Erythromycin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [114]
Etravirine DMGV8QU Moderate Decreased metabolism of Erythromycin caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [115]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Erythromycin caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [116]
Amprenavir DMLMXE0 Major Decreased metabolism of Erythromycin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Darunavir DMN3GCH Moderate Decreased metabolism of Erythromycin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [117]
Atazanavir DMSYRBX Moderate Decreased metabolism of Erythromycin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Maraviroc DMTL94F Moderate Decreased metabolism of Erythromycin caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [118]
Ritonavir DMU764S Major Decreased metabolism of Erythromycin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Simvastatin DM30SGU Major Decreased metabolism of Erythromycin caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [119]
Fluvastatin DM4MDJY Major Decreased metabolism of Erythromycin caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [120]
Lovastatin DM9OZWQ Major Decreased metabolism of Erythromycin caused by Lovastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [119]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Erythromycin and Mipomersen. Hyper-lipoproteinaemia [5C80] [121]
Rosuvastatin DMMIQ7G Minor Altered absorption of Erythromycin due to GI dynamics variation caused by Rosuvastatin. Hyper-lipoproteinaemia [5C80] [122]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Erythromycin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [33]
BMS-201038 DMQTAGO Major Decreased metabolism of Erythromycin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [37]
Cerivastatin DMXCM7H Major Decreased metabolism of Erythromycin caused by Cerivastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [70]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Erythromycin caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [123]
Paricalcitol DMYBV3G Moderate Decreased metabolism of Erythromycin caused by Paricalcitol mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [47]
Aliskiren DM1BV7W Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [33]
Levamlodipine DM92S6N Moderate Decreased metabolism of Erythromycin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [33]
Isradipine DMA5XGH Moderate Decreased metabolism of Erythromycin caused by Isradipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [124]
Verapamil DMA7PEW Major Decreased metabolism of Erythromycin caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [35]
Diltiazem DMAI7ZV Major Decreased metabolism of Erythromycin caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [35]
Amlodipine DMBDAZV Moderate Decreased metabolism of Erythromycin caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [33]
Felodipine DMOSW35 Moderate Decreased metabolism of Erythromycin caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [125]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Erythromycin caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [126]
Fludrocortisone DMUDIR8 Moderate Decreased metabolism of Erythromycin caused by Fludrocortisone mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [124]
Retapamulin DM9JXB7 Minor Decreased metabolism of Erythromycin caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [127]
Rhucin DM3ADGP Major Decreased metabolism of Erythromycin caused by Rhucin mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [37]
Berotralstat DMWA2DZ Major Decreased clearance of Erythromycin due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [128]
Suvorexant DM0E6S3 Major Decreased metabolism of Erythromycin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [129]
Ramelteon DM7IW9J Moderate Decreased metabolism of Erythromycin caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [130]
Eszopiclone DM8RZ9H Moderate Decreased metabolism of Erythromycin caused by Eszopiclone mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [131]
Flurazepam DMAL4G0 Moderate Decreased metabolism of Erythromycin caused by Flurazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [55]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Erythromycin caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [132]
ITI-007 DMUQ1DO Major Decreased metabolism of Erythromycin caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [133]
Zolpidem DMWOSKJ Moderate Decreased metabolism of Erythromycin caused by Zolpidem mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [134]
Quazepam DMY4D87 Moderate Decreased metabolism of Erythromycin caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [55]
Estazolam DMZGXUM Moderate Decreased metabolism of Erythromycin caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [55]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Polyethylene glycol. Irritable bowel syndrome [DD91] [47]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Phenolphthalein. Irritable bowel syndrome [DD91] [33]
Alosetron DML2A03 Moderate Decreased metabolism of Erythromycin caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [135]
Naloxegol DML0B41 Major Decreased metabolism of Erythromycin caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [47]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Erythromycin and Crizotinib. Lung cancer [2C25] [136]
Brigatinib DM7W94S Major Decreased metabolism of Erythromycin caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [37]
Ceritinib DMB920Z Major Decreased metabolism of Erythromycin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [35]
Erlotinib DMCMBHA Moderate Decreased metabolism of Erythromycin caused by Erlotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [137]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Erythromycin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [138]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Erythromycin and Osimertinib. Lung cancer [2C25] [139]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Erythromycin caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [140]
Capmatinib DMYCXKL Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [141]
Selpercatinib DMZR15V Major Decreased metabolism of Erythromycin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [47]
Artemether DM48QOT Major Decreased metabolism of Erythromycin caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [37]
Halofantrine DMOMK1V Major Decreased metabolism of Erythromycin caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [142]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Erythromycin and Chloroquine. Malaria [1F40-1F45] [143]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Erythromycin and Hydroxychloroquine. Malaria [1F40-1F45] [143]
Quinine DMSWYF5 Major Decreased metabolism of Erythromycin caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [144]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Primaquine. Malaria [1F40-1F45] [33]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [47]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [145]
Idelalisib DM602WT Major Decreased metabolism of Erythromycin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [35]
GDC-0199 DMH0QKA Major Decreased metabolism of Erythromycin caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [37]
IPI-145 DMWA24P Moderate Decreased metabolism of Erythromycin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [146]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Erythromycin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [147]
Acalabrutinib DM7GCVW Major Decreased metabolism of Erythromycin caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [148]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Clofarabine. Mature B-cell lymphoma [2A85] [149]
Ibrutinib DMHZCPO Major Decreased metabolism of Erythromycin caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [150]
Vincristine DMINOX3 Major Decreased metabolism of Erythromycin caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [151]
Ponatinib DMYGJQO Moderate Decreased metabolism of Erythromycin caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [152]
Arry-162 DM1P6FR Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Arry-162. Melanoma [2C30] [37]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Erythromycin and Vemurafenib. Melanoma [2C30] [33]
LGX818 DMNQXV8 Major Decreased metabolism of Erythromycin caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [153]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Erythromycin caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [37]
Estrone DM5T6US Moderate Decreased metabolism of Erythromycin caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [37]
Dienestrol DMBSXI0 Moderate Decreased metabolism of Erythromycin caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [37]
Conjugated estrogens DMLT0E1 Moderate Decreased metabolism of Erythromycin caused by Conjugated estrogens mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [37]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Erythromycin caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [37]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Erythromycin caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [33]
Methysergide DM1EF73 Major Decreased metabolism of Erythromycin caused by Methysergide mediated inhibition of CYP450 enzyme. Migraine [8A80] [38]
Dihydroergotamine DM5IKUF Major Decreased metabolism of Erythromycin caused by Dihydroergotamine mediated inhibition of CYP450 enzyme. Migraine [8A80] [105]
Ubrogepant DM749I3 Moderate Decreased metabolism of Erythromycin caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [154]
Almogran DM7I64Z Moderate Decreased metabolism of Erythromycin caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [155]
Rimegepant DMHOAUG Moderate Decreased metabolism of Erythromycin caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [156]
Eletriptan DMW649X Major Decreased metabolism of Erythromycin caused by Eletriptan mediated inhibition of CYP450 enzyme. Migraine [8A80] [157]
Lasmiditan DMXLVDT Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [158]
Exjade DMHPRWG Moderate Decreased metabolism of Erythromycin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [159]
Flibanserin DM70DTN Major Decreased metabolism of Erythromycin caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [160]
Midazolam DMXOELT Moderate Decreased metabolism of Erythromycin caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [37]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Erythromycin and Panobinostat. Multiple myeloma [2A83] [161]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Thalidomide. Multiple myeloma [2A83] [37]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Erythromycin and Siponimod. Multiple sclerosis [8A40] [37]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Erythromycin and Fingolimod. Multiple sclerosis [8A40] [33]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Erythromycin and Ozanimod. Multiple sclerosis [8A40] [162]
Deflazacort DMV0RNS Major Decreased metabolism of Erythromycin caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [47]
Romidepsin DMT5GNL Moderate Decreased metabolism of Erythromycin caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [163]
Fedratinib DM4ZBK6 Minor Decreased metabolism of Erythromycin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [47]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Erythromycin and Nilotinib. Myeloproliferative neoplasm [2A20] [33]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Erythromycin caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [47]
Imatinib DM7RJXL Moderate Decreased metabolism of Erythromycin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [164]
Dasatinib DMJV2EK Major Decreased metabolism of Erythromycin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [37]
Modafinil DMYILBE Minor Decreased metabolism of Erythromycin caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [37]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Erythromycin and Droperidol. Nausea/vomiting [MD90] [33]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Prochlorperazine. Nausea/vomiting [MD90] [33]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Promethazine. Nausea/vomiting [MD90] [33]
Rolapitant DM8XP26 Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [165]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Palonosetron. Nausea/vomiting [MD90] [33]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Granisetron. Nausea/vomiting [MD90] [33]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Erythromycin and Dolasetron. Nausea/vomiting [MD90] [33]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Ondansetron. Nausea/vomiting [MD90] [33]
Entrectinib DMMPTLH Major Decreased metabolism of Erythromycin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [37]
Sibutramine DMFJTDI Minor Decreased metabolism of Erythromycin caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [166]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Erythromycin and Levomethadyl Acetate. Opioid use disorder [6C43] [47]
S-297995 DM26IH8 Moderate Decreased clearance of Erythromycin due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [47]
Valdecoxib DMAY7H4 Moderate Decreased metabolism of Erythromycin caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [167]
Olaparib DM8QB1D Major Decreased metabolism of Erythromycin caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [37]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Rucaparib. Ovarian cancer [2C73] [33]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Dextropropoxyphene. Pain [MG30-MG3Z] [35]
Butorphanol DM5KYPJ Major Decreased metabolism of Erythromycin caused by Butorphanol mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [168]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Erythromycin caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [169]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Erythromycin caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [170]
Oxycodone DMXLKHV Major Decreased metabolism of Erythromycin caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [37]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Triclabendazole. Parasitic worm infestation [1F90] [33]
Istradefylline DM20VSK Moderate Decreased metabolism of Erythromycin caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [171]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Pimavanserin. Parkinsonism [8A00] [172]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Erythromycin caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [47]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Apomorphine. Parkinsonism [8A00] [33]
Abametapir DM2RX0I Moderate Decreased metabolism of Erythromycin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [173]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Famotidine. Peptic ulcer [DA61] [37]
Cabergoline DMQ4HIN Major Decreased metabolism of Erythromycin caused by Cabergoline mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [105]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Erythromycin and Macimorelin. Pituitary gland disorder [5A60-5A61] [174]
Prednisone DM2HG4X Moderate Decreased metabolism of Erythromycin caused by Prednisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [124]
Betamethasone DMAHJEF Moderate Decreased metabolism of Erythromycin caused by Betamethasone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [124]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Erythromycin caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [124]
Ergonovine DM0VEC1 Major Decreased metabolism of Erythromycin caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [38]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Erythromycin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [175]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Ritodrine. Preterm labour/delivery [JB00] [57]
Progesterone DMUY35B Moderate Decreased metabolism of Erythromycin caused by Progesterone mediated inhibition of CYP450 enzyme. Preterm labour/delivery [JB00] [37]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Degarelix. Prostate cancer [2C82] [47]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Erythromycin and ABIRATERONE. Prostate cancer [2C82] [47]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Nilutamide. Prostate cancer [2C82] [47]
Enzalutamide DMGL19D Moderate Accelerated clearance of Erythromycin due to the transporter induction by Enzalutamide. Prostate cancer [2C82] [176]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Flutamide. Prostate cancer [2C82] [47]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Erythromycin and Relugolix. Prostate cancer [2C82] [177]
Darolutamide DMV7YFT Minor Decreased metabolism of Erythromycin caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [178]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Bicalutamide. Prostate cancer [2C82] [47]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Erythromycin caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [179]
Silodosin DMJSBT6 Moderate Decreased metabolism of Erythromycin caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [180]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Erythromycin caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [181]
Alfuzosin DMZVMKF Major Decreased metabolism of Erythromycin caused by Alfuzosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [37]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Levomepromazine. Psychotic disorder [6A20-6A25] [33]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Fluphenazine. Psychotic disorder [6A20-6A25] [33]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Triflupromazine. Psychotic disorder [6A20-6A25] [33]
Ambrisentan DMD1QXW Minor Decreased metabolism of Erythromycin caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [182]
Bosentan DMIOGBU Moderate Decreased metabolism of Erythromycin caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [183]
Riociguat DMXBLMP Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [37]
Everolimus DM8X2EH Major Decreased metabolism of Erythromycin caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [184]
Temsirolimus DMS104F Moderate Decreased metabolism of Erythromycin caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [185]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Sorafenib. Renal cell carcinoma [2C90] [33]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Erythromycin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [36]
Upadacitinib DM32B5U Moderate Decreased metabolism of Erythromycin caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [186]
Tofacitinib DMBS370 Moderate Decreased metabolism of Erythromycin caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [37]
Dexamethasone DMMWZET Moderate Decreased metabolism of Erythromycin caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [124]
Quetiapine DM1N62C Major Decreased metabolism of Erythromycin caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [187]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Erythromycin and Mesoridazine. Schizophrenia [6A20] [33]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Erythromycin and Thioridazine. Schizophrenia [6A20] [33]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Erythromycin caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [188]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Erythromycin and Iloperidone. Schizophrenia [6A20] [33]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Paliperidone. Schizophrenia [6A20] [33]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Erythromycin and Haloperidol. Schizophrenia [6A20] [33]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Perphenazine. Schizophrenia [6A20] [33]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Chlorpromazine. Schizophrenia [6A20] [33]
Clozapine DMFC71L Moderate Decreased metabolism of Erythromycin caused by Clozapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [189]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Trifluoperazine. Schizophrenia [6A20] [33]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Erythromycin and Ziprasidone. Schizophrenia [6A20] [33]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Risperidone. Schizophrenia [6A20] [33]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Olanzapine. Schizophrenia [6A20] [37]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Erythromycin and Amisulpride. Schizophrenia [6A20] [37]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Asenapine. Schizophrenia [6A20] [33]
Pimozide DMW83TP Major Decreased metabolism of Erythromycin caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Fentanyl DM8WAHT Major Decreased metabolism of Erythromycin caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [37]
Avanafil DM75CXN Major Decreased metabolism of Erythromycin caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [190]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Erythromycin caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [37]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Erythromycin and Vardenafil. Sexual dysfunction [HA00-HA01] [37]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Erythromycin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [191]
LDE225 DMM9F25 Major Decreased metabolism of Erythromycin caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [192]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Erythromycin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [47]
Gefitinib DM15F0X Moderate Decreased metabolism of Erythromycin caused by Gefitinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [137]
Larotrectinib DM26CQR Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [37]
Vinblastine DM5TVS3 Major Decreased metabolism of Erythromycin caused by Vinblastine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [151]
Docetaxel DMDI269 Major Decreased clearance of Erythromycin due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [193]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Erythromycin caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [47]
Armodafinil DMGB035 Minor Decreased metabolism of Erythromycin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Erythromycin and LEE011. Solid tumour/cancer [2A00-2F9Z] [33]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [33]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Erythromycin caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [124]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Erythromycin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [194]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [47]
Norethindrone DMTY169 Moderate Decreased metabolism of Erythromycin caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
Taxol DMUOT9V Moderate Decreased metabolism of Erythromycin caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [195]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [33]
Vinorelbine DMVXFYE Major Decreased clearance of Erythromycin due to the transporter inhibition by Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [151]
Pitolisant DM8RFNJ Moderate Increased metabolism of Erythromycin caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [47]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [33]
Ivermectin DMDBX5F Moderate Decreased metabolism of Erythromycin caused by Ivermectin mediated inhibition of CYP450 enzyme. Strongyloidiasis [1F6B] [47]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Naltrexone. Substance abuse [6C40] [196]
Warfarin DMJYCVW Major Decreased metabolism of Erythromycin caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [75]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Erythromycin and Ibutilide. Supraventricular tachyarrhythmia [BC81] [197]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Adenosine. Supraventricular tachyarrhythmia [BC81] [33]
Zithromax DMN4H2O Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Zithromax. Syphilis [1A61-1A6Z] [33]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Erythromycin caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [37]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Erythromycin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [198]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [199]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Erythromycin and Anagrelide. Thrombocytosis [3B63] [33]
Apixaban DM89JLN Moderate Decreased metabolism of Erythromycin caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [47]
Brilinta DMBR01X Moderate Decreased metabolism of Erythromycin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [47]
Dicumarol DMFQCB1 Major Decreased metabolism of Erythromycin caused by Dicumarol mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [47]
Clopidogrel DMOL54H Moderate Decreased metabolism of Erythromycin caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [200]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Lenvatinib. Thyroid cancer [2D10] [33]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Erythromycin and Cabozantinib. Thyroid cancer [2D10] [47]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Erythromycin and Papaverine. Tonus and reflex abnormality [MB47] [201]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Tizanidine. Tonus and reflex abnormality [MB47] [33]
Trimetrexate DMDEA85 Minor Decreased metabolism of Erythromycin caused by Trimetrexate mediated inhibition of CYP450 enzyme. Toxoplasmosis [1F57] [202]
Sirolimus DMGW1ID Major Decreased clearance of Erythromycin due to the transporter inhibition by Sirolimus. Transplant rejection [NE84] [37]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Erythromycin due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [81]
Tacrolimus DMZ7XNQ Major Decreased clearance of Erythromycin due to the transporter inhibition by Tacrolimus. Transplant rejection [NE84] [203]
Saxagliptin DMGXENV Moderate Decreased metabolism of Erythromycin caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [47]
Diethylstilbestrol DMN3UXQ Moderate Decreased metabolism of Erythromycin caused by Diethylstilbestrol mediated inhibition of CYP450 enzyme. Vaginitis [GA02] [37]
Fexofenadine DM17ONX Minor Decreased clearance of Erythromycin due to the transporter inhibition by Fexofenadine. Vasomotor/allergic rhinitis [CA08] [204]
Astemizole DM2HN6Q Major Decreased metabolism of Erythromycin caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [49]
Desloratadine DM56YN7 Minor Decreased metabolism of Erythromycin caused by Desloratadine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [205]
Triamcinolone DM98IXF Moderate Decreased metabolism of Erythromycin caused by Triamcinolone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [124]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [35]
Fluticasone DMGCSVF Minor Decreased metabolism of Erythromycin caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [33]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Erythromycin and Disopyramide. Ventricular tachyarrhythmia [BC71] [37]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Erythromycin and Procainamide. Ventricular tachyarrhythmia [BC71] [33]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Propafenone. Ventricular tachyarrhythmia [BC71] [33]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Flecainide. Ventricular tachyarrhythmia [BC71] [33]
Amiodarone DMUTEX3 Major Decreased metabolism of Erythromycin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [206]
⏷ Show the Full List of 413 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS E00309 24671 Colorant
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Vanillin E00049 1183 Flavoring agent
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
FD&C red no. 3 E00629 Not Available Colorant
Hypromellose E00634 Not Available Coating agent
Lithol rubin BCA E00607 135423095 Colorant
Magnesium aluminum silicate E00462 3084116 Adsorbent; Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Magnesium hydroxide E00374 73981 Adsorbent; Buffering agent
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate E00395 110800 Emollient; Opacifying agent; Surfactant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Sorbic acid E00441 643460 Antimicrobial preservative
Sorbitan monooleate E00503 9920342 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 31 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Erythromycin 250 mg tablet 250 mg Oral Tablet Oral
Erythromycin 500 mg tablet 500 mg Oral Tablet Oral
Erythromycin 250 mg tablet 250 mg Delayed Release Oral Tablet Oral
Erythromycin 500 mg tablet 500 mg Delayed Release Oral Tablet Oral
Erythromycin 333 mg tablet 333 mg Delayed Release Oral Tablet Oral
Erythromycin 400 mg tablet 400 mg Oral Tablet Oral
Erythromycin 250 mg capsule 250 mg Delayed Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Erythromycin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1456).
3 FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension
4 BDDCS applied to over 900 drugs
5 Stanczyk FZ, Roy S: Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 1990 Jul;42(1):67-96.
6 MedSafe NZ: ERA (erythromycin stearate) oral filmtabs
7 Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther. 1996 Jan-Feb;18(1):56-72; discussion 55.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
11 A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
12 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
13 Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
14 ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
15 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
16 Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82.
17 Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
18 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
19 Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
20 Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
21 Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
22 Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
23 Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31.
24 Degradation of various insecticides in cooked eggs during in vitro human digestion. Environ Pollut. 2018 Dec;243(Pt A):437-443.
25 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
26 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
27 Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics. Toxicol In Vitro. 2019 Aug;58:51-59. doi: 10.1016/j.tiv.2019.03.015. Epub 2019 Mar 12.
28 Modulation of steroidogenic gene expression and hormone production of H295R cells by pharmaceuticals and other environmentally active compounds. Toxicol Appl Pharmacol. 2007 Dec 1;225(2):142-53.
29 A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97.
30 Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos. 2004 Dec;32(12):1434-45. doi: 10.1124/dmd.104.001313. Epub 2004 Sep 21.
31 The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology. 2006 Jan 20;218(1):30-8. doi: 10.1016/j.tox.2005.09.014. Epub 2005 Nov 16.
32 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
33 Canadian Pharmacists Association.
34 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
35 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
36 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
37 Cerner Multum, Inc. "Australian Product Information.".
38 Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7. [PMID: 314074]
39 Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):.
40 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
41 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
42 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
43 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
44 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
45 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
46 Multum Information Services, Inc. Expert Review Panel.
47 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
48 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
49 Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223. [PMID: 9225677]
50 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
51 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
52 Geronimo-Pardo M, Cuartero-Del-Pozo AB, Jimenez-Vizuete JM, Cortinas-Saez M, Peyro-Garcia R "Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock." Ann Pharmacother 39 (2005): 538-42. [PMID: 15703161]
53 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
54 Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J "Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance." Pharmacol Toxicol 73 (1993): 180-5. [PMID: 8265524]
55 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
56 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
57 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
58 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
59 Amsden GW "Erythromycin, clarithromycin, and azithromycin: are the differences real?" Clin Ther 18 (1996): 56-72. [PMID: 8851453]
60 Lahu G, Huennemeyer A, Herzog R, et al. "Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide." Int J Clin Pharmacol Ther 47 (2009): 236-45. [PMID: 19356389]
61 Product Information. Elidel (pimecrolimus topical). Novartis Pharmaceuticals, East Hanover, NJ.
62 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
63 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
64 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
65 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
66 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
67 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
68 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
69 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
70 Amsden GW, Kuye O, Wei GC "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers." J Clin Pharmacol 42 (2002): 444-9. [PMID: 11936570]
71 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
72 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73 Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
74 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
75 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E "The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy." Chest 126(3 Suppl) (2004): 204S-233S. [PMID: 15383473]
76 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
77 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
78 Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61. [PMID: 8886604]
79 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
80 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
81 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
82 Morasso MI, Chavez J, Gai MN, Arancibia A "Influence of alcohol consumption on erythromycin ethylsuccinate kinetics." Int J Clin Pharmacol 28 (1990): 426-9. [PMID: 2258252]
83 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
84 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
85 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
86 Lee DO, Lee CD "Serotonin syndrome in a child associated with erythromycin and sertraline." Pharmacotherapy 19 (1999): 894-6. [PMID: 10417041]
87 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
88 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
89 Dattilo PB, Nordin C "Prolonged QT associated with an overdose of trazodone." J Clin Psychiatry 68 (2007): 1309-10. [PMID: 17854263]
90 Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
91 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
92 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
93 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
94 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
95 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
96 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
97 Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L "Single dose phenytoin clearance during erythromycin treatment." Res Commun Chem Pathol Pharmacol 46 (1984): 207-17. [PMID: 6515115]
98 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
99 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
100 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
101 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
102 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
103 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
104 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
105 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
106 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
107 Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.?J Pharmacol Sci. 2010;113(4):315-324. [PMID: 20724802]
108 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
109 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
110 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
111 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
112 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
113 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
114 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
115 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
116 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
117 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
118 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
119 Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
120 Product Information. Lescol (fluvastatin). Novartis Pharmaceuticals, East Hanover, NJ.
121 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
122 Product Information. Crestor (rosuvastatin). AstraZeneca Pharma Inc, Mississauga, ON.
123 Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
124 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
125 Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD "Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice." Clin Pharmacol Ther 60 (1996): 25-33. [PMID: 8689808]
126 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
127 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
128 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
129 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
130 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
131 Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80. [PMID: 11724087]
132 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
133 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
134 Farkas D, Volak L, Harmatz J, von Moltke L, Court M, Greenblatt D "Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem." Clin Pharmacol Ther 85 (2009): 644-50. [PMID: 19242403]
135 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
136 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
137 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
138 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
139 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
140 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
141 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
142 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
143 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
144 Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L "Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man." Eur J Clin Pharmacol 59 (2003): 23-8. [PMID: 12743670]
145 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
146 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
147 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
148 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
149 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
150 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
151 Antoniou T, Tseng AL "Interactions between antiretrovirals and antineoplastic drug therapy." Clin Pharmacokinet 44 (2005): 111-145. [PMID: 15656694]
152 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
153 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
154 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
155 Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
156 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
157 Product Information. Relpax (eletriptan). Pfizer U.S. Pharmaceuticals, New York, NY.
158 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
159 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
160 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
161 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
162 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
163 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
164 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
165 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
166 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
167 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
168 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
169 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
170 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
171 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
172 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
173 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
174 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
175 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
176 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
177 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
178 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
179 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
180 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
181 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
182 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
183 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
184 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
185 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
186 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
187 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
188 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
189 Funderburg LG, Vertrees JE, True JE, Miller AL "Seizure following addition of erythromycin to clozapine treatment." Am J Psychiatry 151 (1994): 1840-1. [PMID: 7977898]
190 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
191 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
192 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
193 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
194 Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
195 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
196 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
197 Gitler B, Berger LS, Buffa SD "Torsades de pointes induced by erythromycin." Chest 105 (1994): 368-72. [PMID: 8306730]
198 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
199 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
200 Clarke TA, Waskell LA "The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin." Drug Metab Dispos 31 (2003): 53-9. [PMID: 12485953]
201 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
202 Product Information. Neutrexin (trimetrexate). US Bioscience, West Conshohocken, PA.
203 Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
204 Product Information. Allegra (fexofenadine). Hoechst Marion-Roussel Inc, Kansas City, MO.
205 Product Information. Clarinex (desloratadine). Schering Corporation, Kenilworth, NJ.
206 Nattel S, Ranger S, Talajic M, et al "Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism." Am J Med 89 (1990): 235-8. [PMID: 2382671]